We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where InflaRx N.V. (NASDAQ:IFRX) stands against the other German stocks.
In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross value in 2021. In contrast, the percentages were 16.8% in France, 18.4% in the USA, and 29% in Japan. Moreover, in 2020, manufacturing companies generated 2,096 billion euros (approximately $2.2 trillion) in revenue. The largest contributor, at 459 billion euros ($485.3 billion), was the automotive market.
According to the aforementioned research report, the manufacturing market’s export ratio in 2021 was 48.4%. Motor cars and motor vehicle parts were Germany’s most important export products in 2022, totaling 244.4 billion euros ($258.4 billion) and accounting for 15.5% of German exports, as in previous years. In this calculation, it is the value of the finished car counts, even though many parts are imported from other countries.
As per Torsten Schrimpf, Partner and International Business Centre Director at Grant Thornton in Germany, the key growth sectors in the country at present include healthcare and medical devices, plastics, and fintech. He claims that there has been an influx of financial services companies over the past few years as a result of Brexit, with many businesses setting up entities in the country or moving away from London entirely.
Nonetheless, currently, the stock market in Germany is under a lot of strain as economic sentiment weakens. The ZEW index dropped rapidly from 13.1 in October to 7.1 in November, falling far short of the 25-point one-year average. Indicating declining confidence among financial specialists, the index measuring the state of the economy also fell by 4.5 points to -91.4. Achim Wambach, a president of ZEW, commented that Germany’s economic sentiment reflects ongoing concerns about trade and political risks, especially in light of recent events in the US. These drops mark a resurgence of worries about rising tariffs and possible trade obstacles affecting European exports in the wake of Donald Trump’s victory as president of the United States. On November 5, 2024, the German DAX index fell by 0.7% in morning trading, confirming this pessimism. The euro also dropped by 0.4% versus the US dollar to a seven-month low of about 1.06, which was made worse by estimates of a stronger dollar due to Trump’s proposed trade policies.
Following Donald Trump’s presidential victory, analysts at Citigroup and ING have voiced a cautious and pessimistic outlook for Germany’s economy. According to Citigroup analysts, Donald Trump’s victory could have a negative impact on German banks because of possible adjustments to interest rates, tariffs, and U.S. financial deregulation. ING analysts also emphasized that auto tariffs might have a “particularly hard hit” on the German economy, which is highly dependent on trade with the U.S. In light of Trump’s critical views on NATO and the Ukraine crisis, this could increase economic uncertainty and erode trust metrics. ING cautioned that while tariffs would not be implemented right away, heightened concerns about trade conflicts might force Germany and the rest of the eurozone into a recession by the end of the year.
Methodology:
To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ and NYSE exchanges. Then we selected 10 stocks that had the highest upside potential. The stocks are ranked in ascending order of the upside potential, as of November 15.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here)
A biochemist in a lab coat surrounded by medical vials and devices used in the development of a biopharmaceutical.
InflaRx N.V. (NASDAQ:IFRX)
Upside potential as of November 15: 233.33%
InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company that uses patented anti-C5a/C5aR technology to identify and develop first-in-class, powerful, and selective inhibitors of the complement activation factor C5a and its receptor, C5aR. The development of several autoimmune and other inflammatory diseases is influenced by the inflammatory mediator C5a.
Vilobelimab, its main product candidate, is a brand-new intravenously administered, first-in-class anti-C5a monoclonal antibody that binds to free C5a specifically and has shown tolerability and disease-modifying clinical activity in a variety of clinical settings.
InflaRx N.V. (NASDAQ:IFRX) recently disclosed its third-quarter 2024 financial results, which demonstrated both continued financial stability and noteworthy clinical trial milestones. The accomplishment of patient recruitment milestones in InflaRx’s Phase 3 Vilobelimab study for pyoderma gangrenosum and the ongoing advancement of their therapeutic pipeline, which is expected to begin a Phase 2a trial for INF904 by the end of 2024, are two of the report’s main highlights. For the first nine months of 2024, InflaRx recorded a net loss of €41.0 million ($43.4 million), which was mostly caused by a decline in other revenue from government grants that terminated in mid-2023. Despite this, the company has €62.0 million ($65.6 million) in cash and marketable securities, which should sustain operations into 2026.
Looking ahead, InflaRx N.V. (NASDAQ:IFRX) is still committed to developing its clinical programs and investigating new market prospects, and it has high hopes for reaching significant milestones in 2025. Positive developments for InflaRx, such as CHMP’s recommendation for Gohibic’s approval for severe COVID-19 ARDS, support the company’s potential for expansion. Despite regulatory obstacles, its commercial outlook is further strengthened by the impending European ruling and continued FDA discussions.
Overall IFRX ranks 3rd on our list of the best German stocks to buy. While we acknowledge the potential of IFRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IFRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
